Novartis Pharmaceuticals to pay $4.4 million to resolve medicaid fraud allegationsChristian Fernsby ▼ | August 7, 2020
Maryland Attorney General Brian E. Frosh announced that Maryland will receive more than $4.4 million to resolve allegations that Novartis Pharmaceuticals Corporation paid kickbacks to health care practitioners in the form of cash, meals, entertainment, and honoraria payments to induce them to prescribe various medications that treat hypertension or Type 2 Diabetes.
Topics: Novartis Pharmaceuticals
“This settlement should be a clear message to drug manufacturers. We are watching, and we will pursue those who attempt to defraud our state.”
From January 2002 through November 2011, it is alleged that Novartis paid kickbacks to doctors to prescribe Lotrel, Valturna, Starlix, Tekamlo, Diovan HCT, Tekturna HCT, and Exforge HCT, and that between January 2010 and November 2011, Novartis did the same for the drugs Exforge, Diovan and Tekturna.
In court documents, it was alleged that Novartis systemically paid doctors to speak about certain drugs at sham events, with a veneer of education applied in an attempt to avoid the law.
Novartis also covered the costs of lavish meals and entertainment to induce doctors to write prescriptions for these Novartis drugs in violation of the Maryland False Health Claims Act.
Novartis admitted to aspects of the scheme in a stipulation filed in federal court in connection with the settlement.
Under the settlement, Novartis agreed to pay $678 million to the United States, Maryland, 26 other states, and the District of Columbia, $103 million of which resolves claims pertaining to state Medicaid programs.
Maryland’s $4.4 million share of the settlement resolves claims relating specifically to Maryland’s Medicaid program. ■